JP7702866B2 - Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート - Google Patents

Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート Download PDF

Info

Publication number
JP7702866B2
JP7702866B2 JP2021527836A JP2021527836A JP7702866B2 JP 7702866 B2 JP7702866 B2 JP 7702866B2 JP 2021527836 A JP2021527836 A JP 2021527836A JP 2021527836 A JP2021527836 A JP 2021527836A JP 7702866 B2 JP7702866 B2 JP 7702866B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021527836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507781A (ja
JP2022507781A5 (https=
JPWO2020106780A5 (https=
Inventor
グロマダ ジャスパー
グサロバ ヴィクトリア
ハン エイミー
ハジナスト ソコル
ジェイ． マーフィー アンドリュー
オルソン ウィリアム
スリーマン マシュー
Original Assignee
レゲネロン ファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レゲネロン ファーマシューティカルス，インコーポレーテッド filed Critical レゲネロン ファーマシューティカルス，インコーポレーテッド
Publication of JP2022507781A publication Critical patent/JP2022507781A/ja
Publication of JP2022507781A5 publication Critical patent/JP2022507781A5/ja
Publication of JPWO2020106780A5 publication Critical patent/JPWO2020106780A5/ja
Priority to JP2025106091A priority Critical patent/JP2025138724A/ja
Application granted granted Critical
Publication of JP7702866B2 publication Critical patent/JP7702866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021527836A 2018-11-20 2019-11-19 Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート Active JP7702866B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106091A JP2025138724A (ja) 2018-11-20 2025-06-24 Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769946P 2018-11-20 2018-11-20
US62/769,946 2018-11-20
PCT/US2019/062302 WO2020106780A1 (en) 2018-11-20 2019-11-19 Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106091A Division JP2025138724A (ja) 2018-11-20 2025-06-24 Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Publications (4)

Publication Number Publication Date
JP2022507781A JP2022507781A (ja) 2022-01-18
JP2022507781A5 JP2022507781A5 (https=) 2022-11-29
JPWO2020106780A5 JPWO2020106780A5 (https=) 2022-11-29
JP7702866B2 true JP7702866B2 (ja) 2025-07-04

Family

ID=69005818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527836A Active JP7702866B2 (ja) 2018-11-20 2019-11-19 Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート
JP2025106091A Pending JP2025138724A (ja) 2018-11-20 2025-06-24 Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106091A Pending JP2025138724A (ja) 2018-11-20 2025-06-24 Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Country Status (20)

Country Link
US (2) US12209180B2 (https=)
EP (2) EP4428142A3 (https=)
JP (2) JP7702866B2 (https=)
KR (1) KR20210094568A (https=)
CN (1) CN113382985A (https=)
AU (1) AU2019384136B2 (https=)
BR (1) BR112021009673A2 (https=)
CA (1) CA3120528A1 (https=)
CL (1) CL2021001308A1 (https=)
CO (1) CO2021007581A2 (https=)
EA (1) EA202191430A1 (https=)
ES (1) ES2984190T3 (https=)
IL (1) IL283313B2 (https=)
MA (1) MA53455B1 (https=)
MX (1) MX2021005822A (https=)
MY (1) MY206542A (https=)
PH (1) PH12021551153A1 (https=)
SG (1) SG11202105175WA (https=)
WO (1) WO2020106780A1 (https=)
ZA (1) ZA202103431B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025138724A (ja) * 2018-11-20 2025-09-25 レゲネロン ファーマシューティカルス，インコーポレーテッド Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CN112533951A (zh) 2018-05-09 2021-03-19 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
KR20240038138A (ko) * 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
CA3198294A1 (en) 2020-11-10 2022-05-19 Thomas Nittoli Selenium antibody conjugates
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US20240408226A1 (en) * 2021-11-02 2024-12-12 Mabplex International Co., Ltd. Antibody drug conjugate intermediate containing sn38 and its preparation method
CN115594766A (zh) * 2021-12-30 2023-01-13 辽宁键凯科技有限公司（Cn） 一种缀合物及用其制备的抗体偶联药物
CN115505028A (zh) * 2022-09-16 2022-12-23 辽宁键凯科技有限公司 一种分支型聚乙二醇连接子及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516327A (ja) 1999-12-13 2003-05-13 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化の予防および／または治療方法
US20030125357A1 (en) 2001-06-11 2003-07-03 Adams Alan D. Therapeutic compounds for treating dyslipidemic conditions
JP2017503847A (ja) 2014-01-27 2017-02-02 ファイザー・インク 二官能性細胞毒性剤
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP1758651A2 (en) 2004-06-24 2007-03-07 Galapagos N.V. Lxr agonists to promote bone homeostasis
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
KR20090094125A (ko) * 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US8993628B2 (en) * 2007-02-23 2015-03-31 City Of Hope Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
KR20140037105A (ko) 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850103C (en) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
CA2850096C (en) 2011-10-14 2018-07-03 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
WO2013055993A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
FI2911699T4 (fi) 2012-10-23 2025-12-09 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
CN105848685B (zh) 2013-12-16 2020-09-22 健泰科生物技术公司 拟肽化合物及其抗体药物偶联物
KR102399277B1 (ko) 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US20160324981A1 (en) * 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
CA3001938A1 (en) * 2015-11-04 2017-05-11 Borealis Ag A process for producing a multilayer laminate
WO2017147542A2 (en) 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
WO2018213082A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
CN112533951A (zh) 2018-05-09 2021-03-19 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
MA53455B1 (fr) * 2018-11-20 2022-11-30 Regeneron Pharma Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516327A (ja) 1999-12-13 2003-05-13 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化の予防および／または治療方法
US20030125357A1 (en) 2001-06-11 2003-07-03 Adams Alan D. Therapeutic compounds for treating dyslipidemic conditions
JP2017503847A (ja) 2014-01-27 2017-02-02 ファイザー・インク 二官能性細胞毒性剤
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COLIN M TICE，THE MEDICINAL CHEMISTRY OF LIVER X RECEPTOR (LXR) MODULATORS，JOURNAL OF MEDICINAL CHEMISTRY，2014年09月11日，VOL:57, NR:17,，PAGE(S):7182 - 7205，http://dx.doi.org/10.1021/jm500442z
COLIN, M. T. et al.，THE MEDICINAL CHEMISTRY OF LIVER X RECEPTOR (LXR) MODULATORS，JOURNAL OF MEDICINAL CHEMISTRY，2014年09月11日，Vol.57, No.17，pp.7182 - 7205，DOI:10.1021/jm500442z
SINGH S B，DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，NL，PERGAMON，2005年06月02日，VOL:15, NR:11,，PAGE(S):2824 - 2828，http://doi.org/10.1016/j.bmcl.2005.03.100
SINGH S B，DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS 以下備考，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，NL，PERGAMON，2005年06月02日，VOL:15, NR:11,，PAGE(S):2824 - 2828，http://doi.org/10.1016/j.bmcl.2005.03.100，OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS
SINGH, S. B. et al.，DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，NL，PERGAMON，2005年06月02日，Vol.15, No.11，pp.2824 - 2828，DOI:10.1016/j.bmcl.2005.03.100
SINGH, S. B. et al.，DISCOVERY AND DEVELOPMENT OF DIMERIC PODOCARPIC ACID LEADS AS POTENT AGONISTS OF LIVER X RECEPTOR WITH HDL CHOLESTEROL RAISING ACTIVITY IN MICE AND HAMSTERS，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，PERGAMON，2005年06月02日，Vol.15, No.11，pp.2824 - 2828，DOI:10.1016/j.bmcl.2005.03.100

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025138724A (ja) * 2018-11-20 2025-09-25 レゲネロン ファーマシューティカルス，インコーポレーテッド Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Also Published As

Publication number Publication date
BR112021009673A2 (pt) 2021-12-14
MA53455B1 (fr) 2022-11-30
WO2020106780A1 (en) 2020-05-28
JP2022507781A (ja) 2022-01-18
KR20210094568A (ko) 2021-07-29
CA3120528A1 (en) 2020-05-28
ZA202103431B (en) 2024-09-25
EP3883926B1 (en) 2024-07-10
AU2019384136B2 (en) 2024-06-06
ES2984190T3 (es) 2024-10-29
EP4428142A2 (en) 2024-09-11
IL283313B2 (en) 2025-08-01
CO2021007581A2 (es) 2021-06-21
AU2019384136A1 (en) 2021-06-10
MX2021005822A (es) 2021-07-15
IL283313B1 (en) 2025-04-01
JP2025138724A (ja) 2025-09-25
US20220080052A1 (en) 2022-03-17
IL283313A (en) 2021-07-29
EP3883926A1 (en) 2021-09-29
US12209180B2 (en) 2025-01-28
PH12021551153A1 (en) 2021-11-03
MA53455A1 (fr) 2021-12-31
CN113382985A (zh) 2021-09-10
EA202191430A1 (ru) 2021-11-29
SG11202105175WA (en) 2021-06-29
CL2021001308A1 (es) 2022-03-11
MY206542A (en) 2024-12-20
US20250171622A1 (en) 2025-05-29
EP4428142A3 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
JP7702866B2 (ja) Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート
JP7843731B2 (ja) ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
JP7426931B2 (ja) 抗体薬物コンジュゲートのための親水性リンカー
JP7617974B2 (ja) シクロデキストリンタンパク質薬物コンジュゲート
JP2025069133A (ja) 無痕跡型リンカー及びそのタンパク質－コンジュゲート
JP2021523147A (ja) 抗ｍｓｒ１抗体及びその使用方法
JP7590328B2 (ja) ツブリシン及びタンパク質－ツブリシンコンジュゲート
JP2023533218A (ja) ツブリシン及びタンパク質－ツブリシンコンジュゲート
HK40116735A (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof
EA049882B1 (ru) Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты
HK40060716B (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
HK40060716A (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
EA047045B1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250624

R150 Certificate of patent or registration of utility model

Ref document number: 7702866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150